{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T13:33:29Z","timestamp":1756992809690,"version":"3.40.5"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.lungcan.2024.107870","type":"journal-article","created":{"date-parts":[[2024,7,3]],"date-time":"2024-07-03T20:35:57Z","timestamp":1720038957000},"page":"107870","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["A phase II study of osimertinib in patients with NSCLC harboring EGFR exon 20 insertion: A multicenter trial of the Korean Cancer Study Group (LU17-19)"],"prefix":"10.1016","volume":"194","author":[{"given":"Yu Jung","family":"Kim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soyeon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tae Min","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koung Jin","family":"Suh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miso","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Se Hyun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bhumsuk","family":"Keam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5124-7132","authenticated-orcid":false,"given":"Dong-Wan","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jong Seok","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dae Seog","family":"Heo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"36","key":"10.1016\/j.lungcan.2024.107870_b0005","doi-asserted-by":"crossref","first-page":"13306","DOI":"10.1073\/pnas.0405220101","article-title":"EGF receptor gene mutations are common in lung cancers from \u201cnever smokers\u201d and are associated with sensitivity of tumors to gefitinib and erlotinib","volume":"101","author":"Pao","year":"2004","journal-title":"PNAS"},{"issue":"5676","key":"10.1016\/j.lungcan.2024.107870_b0010","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1126\/science.1099314","article-title":"EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy","volume":"304","author":"Paez","year":"2004","journal-title":"Science"},{"issue":"21","key":"10.1016\/j.lungcan.2024.107870_b0015","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1056\/NEJMoa040938","article-title":"Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib","volume":"350","author":"Lynch","year":"2004","journal-title":"N. Engl. J. Med."},{"issue":"13","key":"10.1016\/j.lungcan.2024.107870_b0020","doi-asserted-by":"crossref","first-page":"3908","DOI":"10.1158\/1078-0432.CCR-06-0462","article-title":"Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib","volume":"12","author":"Jackman","year":"2006","journal-title":"Clin. Cancer Res."},{"issue":"2","key":"10.1016\/j.lungcan.2024.107870_b0025","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1158\/1535-7163.MCT-12-0620","article-title":"EGFR exon 20 insertion mutations in lung adenocarcinomas: prevalence, molecular heterogeneity, and clinicopathologic characteristics","volume":"12","author":"Arcila","year":"2013","journal-title":"Mol. Cancer Ther."},{"issue":"Suppl 1","key":"10.1016\/j.lungcan.2024.107870_b0030","doi-asserted-by":"crossref","first-page":"S24","DOI":"10.1038\/onc.2009.198","article-title":"Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors","volume":"28","author":"Gazdar","year":"2009","journal-title":"Oncogene"},{"issue":"11","key":"10.1016\/j.lungcan.2024.107870_b0035","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1038\/nm.3388","article-title":"The quest to overcome resistance to EGFR-targeted therapies in cancer","volume":"19","author":"Chong","year":"2013","journal-title":"Nat. Med."},{"issue":"2","key":"10.1016\/j.lungcan.2024.107870_b0040","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer","volume":"378","author":"Soria","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.lungcan.2024.107870_b0045","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1097\/JTO.0b013e3182779d18","article-title":"Natural history and molecular characteristics of lung cancers harboring EGFR exon 20 insertions","volume":"8","author":"Oxnard","year":"2013","journal-title":"J. Thorac. Oncol."},{"issue":"1","key":"10.1016\/j.lungcan.2024.107870_b0050","doi-asserted-by":"crossref","first-page":"e23","DOI":"10.1016\/S1470-2045(11)70129-2","article-title":"EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications","volume":"13","author":"Yasuda","year":"2012","journal-title":"Lancet Oncol."},{"issue":"18","key":"10.1016\/j.lungcan.2024.107870_b0055","doi-asserted-by":"crossref","first-page":"3212","DOI":"10.1002\/cncr.29493","article-title":"Epidermal growth factor receptor exon 20 insertions in advanced lung adenocarcinomas: clinical outcomes and response to erlotinib","volume":"121","author":"Naidoo","year":"2015","journal-title":"Cancer"},{"issue":"216","key":"10.1016\/j.lungcan.2024.107870_b0060","doi-asserted-by":"crossref","first-page":"216ra177","DOI":"10.1126\/scitranslmed.3007205","article-title":"Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer","volume":"5","author":"Yasuda","year":"2013","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.lungcan.2024.107870_b0065","doi-asserted-by":"crossref","unstructured":"Y.Y. Elamin, J.P. Robichaux, B.W. Carter, M. Altan, H. Tran, D.L. Gibbons, S. Heeke, F.V. Fossella, V.K. Lam, X. Le, M.V. Negrao, M.B. Nilsson, A. Patel, R.S.K. Vijayan, J.B. Cross, J. Zhang, L.A. Byers, C. Lu, T. Cascone, L. Feng, R. Luthra, F.A. San Lucas, G. Mantha, M. Routbort, G. Blumenschein, Jr., A.S. Tsao, J.V. Heymach, Poziotinib for EGFR exon 20-mutant NSCLC: Clinical efficacy, resistance mechanisms, and impact of insertion location on drug sensitivity, Cancer Cell 40(7) (2022) 754-767 e6.","DOI":"10.1016\/j.ccell.2022.06.006"},{"issue":"2","key":"10.1016\/j.lungcan.2024.107870_b0070","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S1470-2045(14)71173-8","article-title":"Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials","volume":"16","author":"Yang","year":"2015","journal-title":"Lancet Oncol."},{"issue":"12","key":"10.1016\/j.lungcan.2024.107870_b0075","doi-asserted-by":"crossref","first-page":"e214761","DOI":"10.1001\/jamaoncol.2021.4761","article-title":"Treatment Outcomes and safety of mobocertinib in platinum-pretreated patients with EGFR Exon 20 Insertion-positive metastatic non-small cell lung cancer: a phase 1\/2 open-label nonrandomized clinical trial","volume":"7","author":"Zhou","year":"2021","journal-title":"JAMA Oncol."},{"issue":"30","key":"10.1016\/j.lungcan.2024.107870_b0080","doi-asserted-by":"crossref","first-page":"3391","DOI":"10.1200\/JCO.21.00662","article-title":"Amivantamab in EGFR Exon 20 insertion-mutated non-small-cell lung cancer progressing on platinum chemotherapy: initial results from the CHRYSALIS phase I study","volume":"39","author":"Park","year":"2021","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.lungcan.2024.107870_b0085","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1158\/1535-7163.MCT-17-0758","article-title":"Antitumor activity of osimertinib, an irreversible mutant-selective EGFR tyrosine kinase inhibitor, in NSCLC harboring EGFR Exon 20 insertions","volume":"17","author":"Floc'h","year":"2018","journal-title":"Mol. Cancer Ther."},{"issue":"36","key":"10.1016\/j.lungcan.2024.107870_b0090","doi-asserted-by":"crossref","first-page":"38789","DOI":"10.18632\/oncotarget.5887","article-title":"In vitro modeling to determine mutation specificity of EGFR tyrosine kinase inhibitors against clinically relevant EGFR mutants in non-small-cell lung cancer","volume":"6","author":"Hirano","year":"2015","journal-title":"Oncotarget"},{"issue":"9","key":"10.1016\/j.lungcan.2024.107870_b0095","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1016\/j.jtho.2019.05.006","article-title":"Preclinical modeling of osimertinib for NSCLC with EGFR Exon 20 insertion mutations","volume":"14","author":"Lee","year":"2019","journal-title":"J. Thorac. Oncol."},{"issue":"7","key":"10.1016\/j.lungcan.2024.107870_b0100","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1007\/s13258-020-00949-1","article-title":"A newly developed capture-based sequencing panel for genomic assay of lung cancer","volume":"42","author":"Im","year":"2020","journal-title":"Genes Genomics"},{"issue":"2","key":"10.1016\/j.lungcan.2024.107870_b0105","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.lungcan.2024.107870_b0110","doi-asserted-by":"crossref","first-page":"4181","DOI":"10.2147\/OTT.S108242","article-title":"Clinical efficacy of first-generation EGFR-TKIs in patients with advanced non-small-cell lung cancer harboring EGFR exon 20 mutations","volume":"9","author":"Chen","year":"2016","journal-title":"Onco Targets Ther"},{"issue":"15","key":"10.1016\/j.lungcan.2024.107870_b0115","article-title":"ECOG-ACRIN 5162: a phase II study of osimertinib 160 mg in NSCLC with EGFR exon 20 insertions","volume":"38","author":"Piotrowska","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2024.107870_b0120","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.lungcan.2022.06.012","article-title":"High dose osimertinib in patients with advanced stage EGFR exon 20 mutation-positive NSCLC: results from the phase 2 multicenter POSITION20 trial","volume":"170","author":"Zwierenga","year":"2022","journal-title":"Lung Cancer"},{"issue":"35","key":"10.1016\/j.lungcan.2024.107870_b0125","doi-asserted-by":"crossref","first-page":"E8162","DOI":"10.1073\/pnas.1803152115","article-title":"Altered conformational landscape and dimerization dependency underpins the activation of EGFR by alphaC-beta4 loop insertion mutations","volume":"115","author":"Ruan","year":"2018","journal-title":"PNAS"},{"issue":"10","key":"10.1016\/j.lungcan.2024.107870_b0130","doi-asserted-by":"crossref","first-page":"2712","DOI":"10.1158\/0008-5472.CAN-16-3404","article-title":"Response heterogeneity of EGFR and HER2 Exon 20 insertions to covalent EGFR and HER2 inhibitors","volume":"77","author":"Kosaka","year":"2017","journal-title":"Cancer Res."},{"key":"10.1016\/j.lungcan.2024.107870_b0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2023.102628","article-title":"A comprehensive overview of the heterogeneity of EGFR exon 20 variants in NSCLC and (pre)clinical activity to currently available treatments","volume":"120","author":"Zwierenga","year":"2023","journal-title":"Cancer Treat. Rev."},{"issue":"22","key":"10.1016\/j.lungcan.2024.107870_b0140","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1056\/NEJMoa2306441","article-title":"Amivantamab plus chemotherapy in NSCLC with EGFR Exon 20 insertions","volume":"389","author":"Zhou","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2024.107870_b0145","unstructured":"Takeda Provides Update on EXKIVITY\u00ae (mobocertinib), 2023, pp. https:\/\/www.takeda.com\/newsroom\/newsreleases\/2023\/Takeda-Provides-Update-on-EXKIVITY-mobocertinib\/."}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500224004045?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500224004045?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,8,13]],"date-time":"2024-08-13T22:18:03Z","timestamp":1723587483000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500224004045"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":29,"alternative-id":["S0169500224004045"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2024.107870","relation":{},"ISSN":["0169-5002"],"issn-type":[{"type":"print","value":"0169-5002"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A phase II study of osimertinib in patients with NSCLC harboring EGFR exon 20 insertion: A multicenter trial of the Korean Cancer Study Group (LU17-19)","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2024.107870","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"107870"}}